az-11713908 az-11713908 az-11713908 is a drug developed by astrazeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the cb1 receptor and a partial agonist at cb2. it has poor blood–brain barrier penetration, and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as win 55,212-2. many related benzimidazole-derived cannabinoid ligands are known. az-11713908identifiers iupac name n-(1-(cyclohexylmethyl)-2-((5-ethoxypyridin-2-yl)methyl)-1h-benzoimidazol-5-yl)-n-methylthiophene-2-sulfonamide cas number1309682-69-6 nchemspider26286889 yuniimn7rr3vql7chemical and physical dataformulac27h32n4o3s2molar mass524.70 g·mol−13d model (jsmol)interactive image smiles c5ccsc5s(=o)(=o)n(c)c3ccc1c(c3)nc(cc(cc2)ncc2occ)n1cc4ccccc4 inchi inchi=1s/c27h32n4o3s2/c1-3-34-23-13-11-21(28-18-23)16-26-29-24-17-22(30(2)36(32,33)27-10-7-15-35-27)12-14-25(24)31(26)19-20-8-5-4-6-9-20/h7,10-15,17-18,20h,3-6,8-9,16,19h2,1-2h3 ykey:yievwzczmdykqh-uhfffaoysa-n y ny (what is this?)